Sandra Revill Tremulis: The Major Trial Testing Whether Lp(a) Lowering Saves Lives
Sandra Revill Tremulis, Marketing Consultant at Tremulis Stractical Marketing Consulting and Founder of the Lipoprotein(a) Foundation, shared a post on LinkedIn about a recent article by Leslie Cho et al, published in American Heart Journal:
“ Pelacarsen — the major trial testing whether Lp(a) lowering saves lives
Pelacarsen outcomes program — Lp(a)HORIZON trial design/rationale
Executive summary: Defines the pivotal outcomes framework for Lp(a): large, multinational, placebo-controlled phase 3 trial in established CVD with elevated Lp(a), testing whether targeted Lp(a) lowering reduces MACE. Value for clinicians/researchers: clarifies inclusion thresholds, endpoints, event-driven design, and the intended inferential strategy—useful when interpreting forthcoming results and planning complementary studies (imaging, biomarkers, implementation).
This is one of the most important trials in cardiovascular medicine today.”
Title: Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)
Authors: Leslie Cho , Stephen J Nicholls , Børge G Nordestgaard , Ulf Landmesser , Sotirios Tsimikas , Michael J Blaha , Eran Leitersdorf , A Michael Lincoff , Anastasia Lesogor , Brian Manning , Plamen Kozlovski , Hui Cao , Jing Wang , Steven E Nissen
Read the Full Article in American Heart Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 25, 2026, 10:49Shefina S: From Presenting to Hosting at TRANSCON 2026
-
Sep 25, 2026, 10:37Michelle Leona Cecil: Hemophilia Advocacy and the Power of Community
-
Sep 25, 2026, 10:13Michael Baria: Platelet Concentration and PRP Outcomes in Partial Rotator Cuff Tears
-
Sep 25, 2026, 09:49Haley Coleman: Volunteering to Support Hemophilia Awareness
-
Sep 25, 2026, 08:55Hitarth Mehta: BHMS Students Gain Practical Exposure to Haemophilia Diagnosis
-
Sep 25, 2026, 07:25Varun Capoor: How Therapeutic Apheresis and Transfusion Medicine Can Complement Clinical Management in SCD
-
Sep 25, 2026, 07:14Manshi Kesharwani: SAK-GQDs Modulate Thrombus Burden and Endothelial Function in Deep Vein Thrombosis
-
Sep 25, 2026, 06:20Farjah Hassan Algahtani: How Can We Better Identify Patients at Risk of Blood Clots after Metabolic and Bariatric Surgery?
-
Sep 25, 2026, 05:59Carla Lewis: Kids Conquering Sickle Disease Joins Nemours Children’s Hospital for 2nd Annual Awareness Event